サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1127332

世界の高活性API/HPAPI市場：考察と予測 (2028年まで)

Global High Potency APIs (HPAPI) Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 139 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
世界の高活性API/HPAPI市場：考察と予測 (2028年まで)
出版日: 2022年09月21日
発行: QYResearch
ページ情報: 英文 139 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、高活性API/HPAPI (High Potency APIs (HPAPI)) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 高活性API/HPAPIの製品概要
  • 市場：タイプ別
    • 世界の高活性API/HPAPIの市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Innovative
    • Generic
  • 市場：アプリケーション別
    • 世界の高活性API/HPAPIの市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Oncology
    • Glaucoma
    • Hormonal Imbalance
    • Respiratory Disorders
    • Other
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の高活性API/HPAPIの販売 推定および予測 2017-2028
  • 世界の高活性API/HPAPIの収益 推定および予測 2017-2028
  • 世界の高活性API/HPAPIの収益：地域別: 2017 VS 2021 VS 2028
  • 世界の高活性API/HPAPIの販売：地域別
    • 世界の高活性API/HPAPIの販売：地域別 (2017-2022)
    • 世界の販売 高活性API/HPAPI ：地域別 (2023-2028)
  • 世界の高活性API/HPAPIの収益：地域別
    • 世界の高活性API/HPAPIの収益：地域別 (2017-2022)
    • 世界の高活性API/HPAPIの収益：地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合：メーカー別

  • 世界の高活性API/HPAPIの販売：メーカー別
    • 世界の高活性API/HPAPIの上位メーカー：販売別 (2017-2022)
    • 世界の高活性API/HPAPIの販売市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー： 高活性API/HPAPI2021
  • 世界の高活性API/HPAPIの収益：メーカー別
    • 世界の高活性API/HPAPIの収益：メーカー別 (2017-2022)
    • 世界の高活性API/HPAPIの収益市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5企業： 高活性API/HPAPIの収益 2021
  • 世界の高活性API/HPAPIの販売価格：メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界の高活性API/HPAPIの市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界の高活性API/HPAPIのメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の高活性API/HPAPIの販売：タイプ別
    • 世界の高活性API/HPAPIの販売実績：タイプ別 (2017-2022)
    • 世界の高活性API/HPAPIの販売予測：タイプ別 (2023-2028)
    • 世界の高活性API/HPAPIの販売市場シェア：タイプ別 (2017-2028)
  • 世界の高活性API/HPAPIの収益：タイプ別
    • 世界の高活性API/HPAPIの収益実績：タイプ別 (2017-2022)
    • 世界の高活性API/HPAPIの収益予測：タイプ別 (2023-2028)
    • 世界の高活性API/HPAPIの収益市場シェア：タイプ別 (2017-2028)
  • 世界の高活性API/HPAPIの価格：タイプ別
    • 世界の高活性API/HPAPIの価格：タイプ別 (2017-2022)
    • 世界の高活性API/HPAPIの価格予測：タイプ別 (2023-2028)

第5章 市場規模：アプリケーション別

  • 世界の高活性API/HPAPIの販売：アプリケーション別
    • 世界の高活性API/HPAPIの販売実績：アプリケーション別 (2017-2022)
    • 世界の高活性API/HPAPIの販売予測：アプリケーション別 (2023-2028)
    • 世界の高活性API/HPAPIの販売市場シェア：アプリケーション別 (2017-2028)
  • 世界の高活性API/HPAPIの収益：アプリケーション別
    • 世界の高活性API/HPAPIの収益実績：アプリケーション別 (2017-2022)
    • 世界の高活性API/HPAPIの収益予測：アプリケーション別 (2023-2028)
    • 世界の高活性API/HPAPIの収益市場シェア：アプリケーション別 (2017-2028)
  • 世界の高活性API/HPAPIの価格：アプリケーション別
    • 世界の高活性API/HPAPIの価格：アプリケーション別 (2017-2022)
    • 世界の高活性API/HPAPIの価格予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米の高活性API/HPAPI 市場規模：タイプ別
    • 北米の高活性API/HPAPIの販売：タイプ別 (2017-2028)
    • 北米の高活性API/HPAPIの収益：タイプ別 (2017-2028)
  • 北米の高活性API/HPAPI 市場規模：アプリケーション別
    • 北米の高活性API/HPAPIの販売：アプリケーション別 (2017-2028)
    • 北米の高活性API/HPAPIの収益：アプリケーション別 (2017-2028)
  • 北米の高活性API/HPAPI 市場規模：国別
    • 北米の高活性API/HPAPIの販売：国別 (2017-2028)
    • 北米の高活性API/HPAPIの収益：国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の高活性API/HPAPI 市場規模：タイプ別
    • 欧州の高活性API/HPAPIの販売：タイプ別 (2017-2028)
    • 欧州の高活性API/HPAPIの収益：タイプ別 (2017-2028)
  • 欧州の高活性API/HPAPI 市場規模：アプリケーション別
    • 欧州の高活性API/HPAPIの販売：アプリケーション別 (2017-2028)
    • 欧州の高活性API/HPAPIの収益：アプリケーション別 (2017-2028)
  • 欧州の高活性API/HPAPI 市場規模：国別
    • 欧州の高活性API/HPAPIの販売：国別 (2017-2028)
    • 欧州の高活性API/HPAPIの収益：国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋の高活性API/HPAPI 市場規模：タイプ別
    • アジア太平洋の高活性API/HPAPIの販売：タイプ別 (2017-2028)
    • アジア太平洋の高活性API/HPAPIの収益：タイプ別 (2017-2028)
  • アジア太平洋の高活性API/HPAPI 市場規模：アプリケーション別
    • アジア太平洋の高活性API/HPAPIの販売：アプリケーション別 (2017-2028)
    • アジア太平洋の高活性API/HPAPIの収益：アプリケーション別 (2017-2028)
  • アジア太平洋の高活性API/HPAPI 市場規模：地域別
    • アジア太平洋の高活性API/HPAPIの販売：地域別 (2017-2028)
    • アジア太平洋の高活性API/HPAPIの収益：地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 台湾
    • インドネシア
    • タイ
    • マレーシア
    • フィリピン

第9章 ラテンアメリカ

  • ラテンアメリカの高活性API/HPAPI 市場規模：タイプ別
    • ラテンアメリカの高活性API/HPAPIの販売：タイプ別 (2017-2028)
    • ラテンアメリカの高活性API/HPAPIの収益：タイプ別 (2017-2028)
  • ラテンアメリカの高活性API/HPAPI 市場規模：アプリケーション別
    • ラテンアメリカの高活性API/HPAPIの販売：アプリケーション別 (2017-2028)
    • ラテンアメリカの高活性API/HPAPIの収益：アプリケーション別 (2017-2028)
  • ラテンアメリカの高活性API/HPAPI 市場規模：国別
    • ラテンアメリカの高活性API/HPAPIの販売：国別 (2017-2028)
    • ラテンアメリカの高活性API/HPAPIの収益：国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカの高活性API/HPAPI 市場規模：タイプ別
    • 中東・アフリカの高活性API/HPAPIの販売：タイプ別 (2017-2028)
    • 中東・アフリカの高活性API/HPAPIの収益：タイプ別 (2017-2028)
  • 中東・アフリカの高活性API/HPAPI 市場規模：アプリケーション別
    • 中東・アフリカの高活性API/HPAPIの販売：アプリケーション別 (2017-2028)
    • 中東・アフリカの高活性API/HPAPIの収益：アプリケーション別 (2017-2028)
  • 中東・アフリカの高活性API/HPAPI 市場規模：国別
    • 中東・アフリカの高活性API/HPAPIの販売：国別 (2017-2028)
    • 中東・アフリカの高活性API/HPAPIの収益：国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • Pfizer (US)
  • Novartis (Switzerland)
  • Sanofi (France)
  • Roche (Switzerland)
  • Eli Lilly and Company (US)
  • Merck (US)
  • AbbVie (US)
  • Boehringer Ingelheim (Germany)
  • GlaxoSmithKline (UK)
  • RAG-Stiftung (Germany)
  • Bristol-Myers Squibb (US)
  • Teva (Israel)
  • Mylan (US)
  • AstraZeneca (UK)
  • Lonza (Swiss)
  • Ash Stevens (US)
  • AMRI (US)

第12章 業界チェーンと販売チャネルの分析

  • 高活性API/HPAPI 業界チェーン分析
  • 高活性API/HPAPI 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • 高活性API/HPAPI 生産形態とプロセス
  • 高活性API/HPAPI 販売およびマーケティング
    • 高活性API/HPAPI 販売チャネル
    • 高活性API/HPAPI 卸業者
  • 高活性API/HPAPI 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • 高活性API/HPAPI 業界動向
  • 高活性API/HPAPI 市場の促進要因
  • 高活性API/HPAPI 市場の課題
  • 高活性API/HPAPI 市場の抑制要因

第14章 世界の高活性API/HPAPIの主な市場調査結果

第15章 付録

図表
  • Table 1. Global High Potency APIs (HPAPI) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Innovative
  • Table 3. Major Manufacturers of Generic
  • Table 4. Global High Potency APIs (HPAPI) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 5. Global High Potency APIs (HPAPI) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 6. Global High Potency APIs (HPAPI) Sales by Region (2017-2022) & (KG)
  • Table 7. Global High Potency APIs (HPAPI) Sales Market Share by Region (2017-2022)
  • Table 8. Global High Potency APIs (HPAPI) Sales by Region (2023-2028) & (KG)
  • Table 9. Global High Potency APIs (HPAPI) Sales Market Share by Region (2023-2028)
  • Table 10. Global High Potency APIs (HPAPI) Revenue by Region (2017-2022) & (US$ Million)
  • Table 11. Global High Potency APIs (HPAPI) Revenue Market Share by Region (2017-2022)
  • Table 12. Global High Potency APIs (HPAPI) Revenue by Region (2023-2028) & (US$ Million)
  • Table 13. Global High Potency APIs (HPAPI) Revenue Market Share by Region (2023-2028)
  • Table 14. Global High Potency APIs (HPAPI) Sales by Manufacturers (2017-2022) & (KG)
  • Table 15. Global High Potency APIs (HPAPI) Sales Share by Manufacturers (2017-2022)
  • Table 16. Global High Potency APIs (HPAPI) Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 17. Global High Potency APIs (HPAPI) Revenue Share by Manufacturers (2017-2022)
  • Table 18. High Potency APIs (HPAPI) Price by Manufacturers (2017-2022) &(USD/KG)
  • Table 19. Global High Potency APIs (HPAPI) Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 20. Global High Potency APIs (HPAPI) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in High Potency APIs (HPAPI) as of 2021)
  • Table 21. High Potency APIs (HPAPI) Manufacturing Base Distribution and Headquarters
  • Table 22. Manufacturers High Potency APIs (HPAPI) Product Offered
  • Table 23. Date of Manufacturers Enter into High Potency APIs (HPAPI) Market
  • Table 24. Mergers & Acquisitions, Expansion Plans
  • Table 25. Global High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 26. Global High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 27. Global High Potency APIs (HPAPI) Sales Share by Type (2017-2022)
  • Table 28. Global High Potency APIs (HPAPI) Sales Share by Type (2023-2028)
  • Table 29. Global High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 30. Global High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 31. Global High Potency APIs (HPAPI) Revenue Share by Type (2017-2022)
  • Table 32. Global High Potency APIs (HPAPI) Revenue Share by Type (2023-2028)
  • Table 33. High Potency APIs (HPAPI) Price by Type (2017-2022) & (USD/KG)
  • Table 34. Global High Potency APIs (HPAPI) Price Forecast by Type (2023-2028) & (USD/KG)
  • Table 35. Global High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 36. Global High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 37. Global High Potency APIs (HPAPI) Sales Share by Application (2017-2022)
  • Table 38. Global High Potency APIs (HPAPI) Sales Share by Application (2023-2028)
  • Table 39. Global High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 40. Global High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 41. Global High Potency APIs (HPAPI) Revenue Share by Application (2017-2022)
  • Table 42. Global High Potency APIs (HPAPI) Revenue Share by Application (2023-2028)
  • Table 43. High Potency APIs (HPAPI) Price by Application (2017-2022) & (USD/KG)
  • Table 44. Global High Potency APIs (HPAPI) Price Forecast by Application (2023-2028) & (USD/KG)
  • Table 45. North America High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 46. North America High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 47. North America High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 48. North America High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 49. North America High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 50. North America High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 51. North America High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 52. North America High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 53. North America High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
  • Table 54. North America High Potency APIs (HPAPI) Sales by Country (2023-2028) & (KG)
  • Table 55. North America High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
  • Table 56. North America High Potency APIs (HPAPI) Revenue by Country (2023-2028) & (US$ Million)
  • Table 57. Europe High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 58. Europe High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 59. Europe High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 60. Europe High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 61. Europe High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 62. Europe High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 63. Europe High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 64. Europe High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 65. Europe High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
  • Table 66. Europe High Potency APIs (HPAPI) Sales by Country (2023-2028) & (KG)
  • Table 67. Europe High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
  • Table 68. Europe High Potency APIs (HPAPI) Revenue by Country (2023-2028) & (US$ Million)
  • Table 69. Asia Pacific High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 70. Asia Pacific High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 71. Asia Pacific High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 72. Asia Pacific High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 73. Asia Pacific High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 74. Asia Pacific High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 75. Asia Pacific High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 76. Asia Pacific High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 77. Asia Pacific High Potency APIs (HPAPI) Sales by Region (2017-2022) & (KG)
  • Table 78. Asia Pacific High Potency APIs (HPAPI) Sales by Region (2023-2028) & (KG)
  • Table 79. Asia Pacific High Potency APIs (HPAPI) Revenue by Region (2017-2022) & (US$ Million)
  • Table 80. Asia Pacific High Potency APIs (HPAPI) Revenue by Region (2023-2028) & (US$ Million)
  • Table 81. Latin America High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 82. Latin America High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 83. Latin America High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 84. Latin America High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 85. Latin America High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 86. Latin America High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 87. Latin America High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 88. Latin America High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 89. Latin America High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
  • Table 90. Latin America High Potency APIs (HPAPI) Sales by Country (2023-2028) & (KG)
  • Table 91. Latin America High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
  • Table 92. Latin America High Potency APIs (HPAPI) Revenue by Country (2023-2028) & (US$ Million)
  • Table 93. Middle East and Africa High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
  • Table 94. Middle East and Africa High Potency APIs (HPAPI) Sales by Type (2023-2028) & (KG)
  • Table 95. Middle East and Africa High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
  • Table 96. Middle East and Africa High Potency APIs (HPAPI) Revenue by Type (2023-2028) & (US$ Million)
  • Table 97. Middle East and Africa High Potency APIs (HPAPI) Sales by Application (2017-2022) & (KG)
  • Table 98. Middle East and Africa High Potency APIs (HPAPI) Sales by Application (2023-2028) & (KG)
  • Table 99. Middle East and Africa High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
  • Table 100. Middle East and Africa High Potency APIs (HPAPI) Revenue by Application (2023-2028) & (US$ Million)
  • Table 101. Middle East and Africa High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
  • Table 102. Middle East and Africa High Potency APIs (HPAPI) Sales by Country (2023-2028) & (KG)
  • Table 103. Middle East and Africa High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
  • Table 104. Middle East and Africa High Potency APIs (HPAPI) Revenue by Country (2023-2028) & (US$ Million)
  • Table 105. Pfizer (US) Corporation Information
  • Table 106. Pfizer (US) Description and Major Businesses
  • Table 107. Pfizer (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 108. Pfizer (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 109. Pfizer (US) Recent Developments
  • Table 110. Novartis (Switzerland) Corporation Information
  • Table 111. Novartis (Switzerland) Description and Major Businesses
  • Table 112. Novartis (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 113. Novartis (Switzerland) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 114. Novartis (Switzerland) Recent Developments
  • Table 115. Sanofi (France) Corporation Information
  • Table 116. Sanofi (France) Description and Major Businesses
  • Table 117. Sanofi (France) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 118. Sanofi (France) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 119. Sanofi (France) Recent Developments
  • Table 120. Roche (Switzerland) Corporation Information
  • Table 121. Roche (Switzerland) Description and Major Businesses
  • Table 122. Roche (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 123. Roche (Switzerland) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 124. Roche (Switzerland) Recent Developments
  • Table 125. Eli Lilly and Company (US) Corporation Information
  • Table 126. Eli Lilly and Company (US) Description and Major Businesses
  • Table 127. Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 128. Eli Lilly and Company (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 129. Eli Lilly and Company (US) Recent Developments
  • Table 130. Merck (US) Corporation Information
  • Table 131. Merck (US) Description and Major Businesses
  • Table 132. Merck (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 133. Merck (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 134. Merck (US) Recent Developments
  • Table 135. AbbVie (US) Corporation Information
  • Table 136. AbbVie (US) Description and Major Businesses
  • Table 137. AbbVie (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 138. AbbVie (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 139. AbbVie (US) Recent Developments
  • Table 140. Boehringer Ingelheim (Germany) Corporation Information
  • Table 141. Boehringer Ingelheim (Germany) Description and Major Businesses
  • Table 142. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 143. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 144. Boehringer Ingelheim (Germany) Recent Developments
  • Table 145. GlaxoSmithKline (UK) Corporation Information
  • Table 146. GlaxoSmithKline (UK) Description and Major Businesses
  • Table 147. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 148. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 149. GlaxoSmithKline (UK) Recent Developments
  • Table 150. RAG-Stiftung (Germany) Corporation Information
  • Table 151. RAG-Stiftung (Germany) Description and Major Businesses
  • Table 152. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 153. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 154. RAG-Stiftung (Germany) Recent Developments
  • Table 155. Bristol-Myers Squibb (US) Corporation Information
  • Table 156. Bristol-Myers Squibb (US) Description and Major Businesses
  • Table 157. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 158. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 159. Bristol-Myers Squibb (US) Recent Developments
  • Table 160. Teva (Israel) Corporation Information
  • Table 161. Teva (Israel) Description and Major Businesses
  • Table 162. Teva (Israel) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 163. Teva (Israel) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 164. Teva (Israel) Recent Developments
  • Table 165. Mylan (US) Corporation Information
  • Table 166. Mylan (US) Description and Major Businesses
  • Table 167. Mylan (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 168. Mylan (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 169. Mylan (US) Recent Developments
  • Table 170. AstraZeneca (UK) Corporation Information
  • Table 171. AstraZeneca (UK) Description and Major Businesses
  • Table 172. AstraZeneca (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 173. AstraZeneca (UK) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 174. AstraZeneca (UK) Recent Developments
  • Table 175. Lonza (Swiss) Corporation Information
  • Table 176. Lonza (Swiss) Description and Major Businesses
  • Table 177. Lonza (Swiss) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 178. Lonza (Swiss) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 179. Lonza (Swiss) Recent Developments
  • Table 180. Ash Stevens (US) Corporation Information
  • Table 181. Ash Stevens (US) Description and Major Businesses
  • Table 182. Ash Stevens (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 183. Ash Stevens (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 184. Ash Stevens (US) Recent Developments
  • Table 185. AMRI (US) Corporation Information
  • Table 186. AMRI (US) Description and Major Businesses
  • Table 187. AMRI (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
  • Table 188. AMRI (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 189. AMRI (US) Recent Developments
  • Table 190. Key Raw Materials Lists
  • Table 191. Raw Materials Key Suppliers Lists
  • Table 192. High Potency APIs (HPAPI) Distributors List
  • Table 193. High Potency APIs (HPAPI) Customers List
  • Table 194. High Potency APIs (HPAPI) Market Trends
  • Table 195. High Potency APIs (HPAPI) Market Drivers
  • Table 196. High Potency APIs (HPAPI) Market Challenges
  • Table 197. High Potency APIs (HPAPI) Market Restraints
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources

List of Figures

  • Figure 1. High Potency APIs (HPAPI) Product Picture
  • Figure 3. Global High Potency APIs (HPAPI) Market Share by Type in 2021 & 2028
  • Figure 3. Innovative Product Picture
  • Figure 4. Generic Product Picture
  • Figure 5. Global High Potency APIs (HPAPI) Market Share by Application in 2021 & 2028
  • Figure 6. Oncology
  • Figure 7. Glaucoma
  • Figure 8. Hormonal Imbalance
  • Figure 9. Respiratory Disorders
  • Figure 10. Other
  • Figure 11. High Potency APIs (HPAPI) Report Years Considered
  • Figure 12. Global High Potency APIs (HPAPI) Sales 2017-2028 (KG)
  • Figure 13. Global High Potency APIs (HPAPI) Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 14. Global High Potency APIs (HPAPI) Revenue 2017-2028 (US$ Million)
  • Figure 15. Global High Potency APIs (HPAPI) Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 16. Global High Potency APIs (HPAPI) Sales Market Share by Region (2017-2022)
  • Figure 17. Global High Potency APIs (HPAPI) Sales Market Share by Region (2023-2028)
  • Figure 18. North America High Potency APIs (HPAPI) Sales YoY (2017-2028) & (KG)
  • Figure 19. North America High Potency APIs (HPAPI) Revenue YoY (2017-2028) & (US$ Million)
  • Figure 20. Europe High Potency APIs (HPAPI) Sales YoY (2017-2028) & (KG)
  • Figure 21. Europe High Potency APIs (HPAPI) Revenue YoY (2017-2028) & (US$ Million)
  • Figure 22. Asia-Pacific High Potency APIs (HPAPI) Sales YoY (2017-2028) & (KG)
  • Figure 23. Asia-Pacific High Potency APIs (HPAPI) Revenue YoY (2017-2028) & (US$ Million)
  • Figure 24. Latin America High Potency APIs (HPAPI) Sales YoY (2017-2028) & (KG)
  • Figure 25. Latin America High Potency APIs (HPAPI) Revenue YoY (2017-2028) & (US$ Million)
  • Figure 26. Middle East & Africa High Potency APIs (HPAPI) Sales YoY (2017-2028) & (KG)
  • Figure 27. Middle East & Africa High Potency APIs (HPAPI) Revenue YoY (2017-2028) & (US$ Million)
  • Figure 28. The High Potency APIs (HPAPI) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 29. The Top 5 and 10 Largest Manufacturers of High Potency APIs (HPAPI) in the World: Market Share by High Potency APIs (HPAPI) Revenue in 2021
  • Figure 30. Global High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 31. Global High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 32. Global High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 33. Global High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 34. Global High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 35. North America High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 36. North America High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 37. North America High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 38. North America High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 39. North America High Potency APIs (HPAPI) Sales Share by Country (2017-2028)
  • Figure 40. North America High Potency APIs (HPAPI) Revenue Share by Country (2017-2028)
  • Figure 41. U.S. High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 42. Canada High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 43. Europe High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 44. Europe High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 45. Europe High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 46. Europe High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 47. Europe High Potency APIs (HPAPI) Sales Share by Country (2017-2028)
  • Figure 48. Europe High Potency APIs (HPAPI) Revenue Share by Country (2017-2028)
  • Figure 49. Germany High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 50. France High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 51. U.K. High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 52. Italy High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 53. Russia High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 54. Asia Pacific High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 55. Asia Pacific High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 56. Asia Pacific High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 57. Asia Pacific High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 58. Asia Pacific High Potency APIs (HPAPI) Sales Share by Region (2017-2028)
  • Figure 59. Asia Pacific High Potency APIs (HPAPI) Revenue Share by Region (2017-2028)
  • Figure 60. China High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 61. Japan High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 62. South Korea High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 63. India High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 64. Australia High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 65. Taiwan High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 66. Indonesia High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 67. Thailand High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 68. Malaysia High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 69. Philippines High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 70. Latin America High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 71. Latin America High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 72. Latin America High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 73. Latin America High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 74. Latin America High Potency APIs (HPAPI) Sales Share by Country (2017-2028)
  • Figure 75. Latin America High Potency APIs (HPAPI) Revenue Share by Country (2017-2028)
  • Figure 76. Mexico High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 77. Brazil High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 78. Argentina High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 79. Middle East and Africa High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • Figure 80. Middle East and Africa High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • Figure 81. Middle East and Africa High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • Figure 82. Middle East and Africa High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • Figure 83. Middle East and Africa High Potency APIs (HPAPI) Sales Share by Country (2017-2028)
  • Figure 84. Middle East and Africa High Potency APIs (HPAPI) Revenue Share by Country (2017-2028)
  • Figure 85. Turkey High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 86. Saudi Arabia High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 87. UAE High Potency APIs (HPAPI) Revenue (2017-2028) & (US$ Million)
  • Figure 88. High Potency APIs (HPAPI) Value Chain
  • Figure 89. High Potency APIs (HPAPI) Production Process
  • Figure 90. Channels of Distribution
  • Figure 91. Distributors Profiles
  • Figure 92. Bottom-up and Top-down Approaches for This Report
  • Figure 93. Data Triangulation
  • Figure 94. Key Executives Interviewed
目次

This research report focuses on the High Potency APIs (HPAPI) Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 High Potency APIs (HPAPI) Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global High Potency APIs (HPAPI) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Innovative
    • 1.2.3 Generic
  • 1.3 Market by Application
    • 1.3.1 Global High Potency APIs (HPAPI) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Oncology
    • 1.3.3 Glaucoma
    • 1.3.4 Hormonal Imbalance
    • 1.3.5 Respiratory Disorders
    • 1.3.6 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global High Potency APIs (HPAPI) Sales Estimates and Forecasts 2017-2028
  • 2.2 Global High Potency APIs (HPAPI) Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global High Potency APIs (HPAPI) Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global High Potency APIs (HPAPI) Sales by Region
    • 2.4.1 Global High Potency APIs (HPAPI) Sales by Region (2017-2022)
    • 2.4.2 Global Sales High Potency APIs (HPAPI) by Region (2023-2028)
  • 2.5 Global High Potency APIs (HPAPI) Revenue by Region
    • 2.5.1 Global High Potency APIs (HPAPI) Revenue by Region (2017-2022)
    • 2.5.2 Global High Potency APIs (HPAPI) Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global High Potency APIs (HPAPI) Sales by Manufacturers
    • 3.1.1 Global Top High Potency APIs (HPAPI) Manufacturers by Sales (2017-2022)
    • 3.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of High Potency APIs (HPAPI) in 2021
  • 3.2 Global High Potency APIs (HPAPI) Revenue by Manufacturers
    • 3.2.1 Global High Potency APIs (HPAPI) Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global High Potency APIs (HPAPI) Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by High Potency APIs (HPAPI) Revenue in 2021
  • 3.3 Global High Potency APIs (HPAPI) Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global High Potency APIs (HPAPI) Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global High Potency APIs (HPAPI) Sales by Type
    • 4.1.1 Global High Potency APIs (HPAPI) Historical Sales by Type (2017-2022)
    • 4.1.2 Global High Potency APIs (HPAPI) Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global High Potency APIs (HPAPI) Sales Market Share by Type (2017-2028)
  • 4.2 Global High Potency APIs (HPAPI) Revenue by Type
    • 4.2.1 Global High Potency APIs (HPAPI) Historical Revenue by Type (2017-2022)
    • 4.2.2 Global High Potency APIs (HPAPI) Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2028)
  • 4.3 Global High Potency APIs (HPAPI) Price by Type
    • 4.3.1 Global High Potency APIs (HPAPI) Price by Type (2017-2022)
    • 4.3.2 Global High Potency APIs (HPAPI) Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global High Potency APIs (HPAPI) Sales by Application
    • 5.1.1 Global High Potency APIs (HPAPI) Historical Sales by Application (2017-2022)
    • 5.1.2 Global High Potency APIs (HPAPI) Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global High Potency APIs (HPAPI) Sales Market Share by Application (2017-2028)
  • 5.2 Global High Potency APIs (HPAPI) Revenue by Application
    • 5.2.1 Global High Potency APIs (HPAPI) Historical Revenue by Application (2017-2022)
    • 5.2.2 Global High Potency APIs (HPAPI) Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2028)
  • 5.3 Global High Potency APIs (HPAPI) Price by Application
    • 5.3.1 Global High Potency APIs (HPAPI) Price by Application (2017-2022)
    • 5.3.2 Global High Potency APIs (HPAPI) Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America High Potency APIs (HPAPI) Market Size by Type
    • 6.1.1 North America High Potency APIs (HPAPI) Sales by Type (2017-2028)
    • 6.1.2 North America High Potency APIs (HPAPI) Revenue by Type (2017-2028)
  • 6.2 North America High Potency APIs (HPAPI) Market Size by Application
    • 6.2.1 North America High Potency APIs (HPAPI) Sales by Application (2017-2028)
    • 6.2.2 North America High Potency APIs (HPAPI) Revenue by Application (2017-2028)
  • 6.3 North America High Potency APIs (HPAPI) Market Size by Country
    • 6.3.1 North America High Potency APIs (HPAPI) Sales by Country (2017-2028)
    • 6.3.2 North America High Potency APIs (HPAPI) Revenue by Country (2017-2028)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe High Potency APIs (HPAPI) Market Size by Type
    • 7.1.1 Europe High Potency APIs (HPAPI) Sales by Type (2017-2028)
    • 7.1.2 Europe High Potency APIs (HPAPI) Revenue by Type (2017-2028)
  • 7.2 Europe High Potency APIs (HPAPI) Market Size by Application
    • 7.2.1 Europe High Potency APIs (HPAPI) Sales by Application (2017-2028)
    • 7.2.2 Europe High Potency APIs (HPAPI) Revenue by Application (2017-2028)
  • 7.3 Europe High Potency APIs (HPAPI) Market Size by Country
    • 7.3.1 Europe High Potency APIs (HPAPI) Sales by Country (2017-2028)
    • 7.3.2 Europe High Potency APIs (HPAPI) Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific High Potency APIs (HPAPI) Market Size by Type
    • 8.1.1 Asia Pacific High Potency APIs (HPAPI) Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Type (2017-2028)
  • 8.2 Asia Pacific High Potency APIs (HPAPI) Market Size by Application
    • 8.2.1 Asia Pacific High Potency APIs (HPAPI) Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Application (2017-2028)
  • 8.3 Asia Pacific High Potency APIs (HPAPI) Market Size by Region
    • 8.3.1 Asia Pacific High Potency APIs (HPAPI) Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America High Potency APIs (HPAPI) Market Size by Type
    • 9.1.1 Latin America High Potency APIs (HPAPI) Sales by Type (2017-2028)
    • 9.1.2 Latin America High Potency APIs (HPAPI) Revenue by Type (2017-2028)
  • 9.2 Latin America High Potency APIs (HPAPI) Market Size by Application
    • 9.2.1 Latin America High Potency APIs (HPAPI) Sales by Application (2017-2028)
    • 9.2.2 Latin America High Potency APIs (HPAPI) Revenue by Application (2017-2028)
  • 9.3 Latin America High Potency APIs (HPAPI) Market Size by Country
    • 9.3.1 Latin America High Potency APIs (HPAPI) Sales by Country (2017-2028)
    • 9.3.2 Latin America High Potency APIs (HPAPI) Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa High Potency APIs (HPAPI) Market Size by Type
    • 10.1.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa High Potency APIs (HPAPI) Market Size by Application
    • 10.2.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa High Potency APIs (HPAPI) Market Size by Country
    • 10.3.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 Pfizer (US)
    • 11.1.1 Pfizer (US) Corporation Information
    • 11.1.2 Pfizer (US) Overview
    • 11.1.3 Pfizer (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 Pfizer (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Pfizer (US) Recent Developments
  • 11.2 Novartis (Switzerland)
    • 11.2.1 Novartis (Switzerland) Corporation Information
    • 11.2.2 Novartis (Switzerland) Overview
    • 11.2.3 Novartis (Switzerland) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 Novartis (Switzerland) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Novartis (Switzerland) Recent Developments
  • 11.3 Sanofi (France)
    • 11.3.1 Sanofi (France) Corporation Information
    • 11.3.2 Sanofi (France) Overview
    • 11.3.3 Sanofi (France) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 Sanofi (France) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Sanofi (France) Recent Developments
  • 11.4 Roche (Switzerland)
    • 11.4.1 Roche (Switzerland) Corporation Information
    • 11.4.2 Roche (Switzerland) Overview
    • 11.4.3 Roche (Switzerland) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 Roche (Switzerland) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Roche (Switzerland) Recent Developments
  • 11.5 Eli Lilly and Company (US)
    • 11.5.1 Eli Lilly and Company (US) Corporation Information
    • 11.5.2 Eli Lilly and Company (US) Overview
    • 11.5.3 Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 Eli Lilly and Company (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Eli Lilly and Company (US) Recent Developments
  • 11.6 Merck (US)
    • 11.6.1 Merck (US) Corporation Information
    • 11.6.2 Merck (US) Overview
    • 11.6.3 Merck (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Merck (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Merck (US) Recent Developments
  • 11.7 AbbVie (US)
    • 11.7.1 AbbVie (US) Corporation Information
    • 11.7.2 AbbVie (US) Overview
    • 11.7.3 AbbVie (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.7.4 AbbVie (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 AbbVie (US) Recent Developments
  • 11.8 Boehringer Ingelheim (Germany)
    • 11.8.1 Boehringer Ingelheim (Germany) Corporation Information
    • 11.8.2 Boehringer Ingelheim (Germany) Overview
    • 11.8.3 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.8.4 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Boehringer Ingelheim (Germany) Recent Developments
  • 11.9 GlaxoSmithKline (UK)
    • 11.9.1 GlaxoSmithKline (UK) Corporation Information
    • 11.9.2 GlaxoSmithKline (UK) Overview
    • 11.9.3 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.9.4 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 GlaxoSmithKline (UK) Recent Developments
  • 11.10 RAG-Stiftung (Germany)
    • 11.10.1 RAG-Stiftung (Germany) Corporation Information
    • 11.10.2 RAG-Stiftung (Germany) Overview
    • 11.10.3 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.10.4 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 RAG-Stiftung (Germany) Recent Developments
  • 11.11 Bristol-Myers Squibb (US)
    • 11.11.1 Bristol-Myers Squibb (US) Corporation Information
    • 11.11.2 Bristol-Myers Squibb (US) Overview
    • 11.11.3 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.11.4 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.11.5 Bristol-Myers Squibb (US) Recent Developments
  • 11.12 Teva (Israel)
    • 11.12.1 Teva (Israel) Corporation Information
    • 11.12.2 Teva (Israel) Overview
    • 11.12.3 Teva (Israel) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.12.4 Teva (Israel) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.12.5 Teva (Israel) Recent Developments
  • 11.13 Mylan (US)
    • 11.13.1 Mylan (US) Corporation Information
    • 11.13.2 Mylan (US) Overview
    • 11.13.3 Mylan (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.13.4 Mylan (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.13.5 Mylan (US) Recent Developments
  • 11.14 AstraZeneca (UK)
    • 11.14.1 AstraZeneca (UK) Corporation Information
    • 11.14.2 AstraZeneca (UK) Overview
    • 11.14.3 AstraZeneca (UK) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.14.4 AstraZeneca (UK) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.14.5 AstraZeneca (UK) Recent Developments
  • 11.15 Lonza (Swiss)
    • 11.15.1 Lonza (Swiss) Corporation Information
    • 11.15.2 Lonza (Swiss) Overview
    • 11.15.3 Lonza (Swiss) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.15.4 Lonza (Swiss) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.15.5 Lonza (Swiss) Recent Developments
  • 11.16 Ash Stevens (US)
    • 11.16.1 Ash Stevens (US) Corporation Information
    • 11.16.2 Ash Stevens (US) Overview
    • 11.16.3 Ash Stevens (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.16.4 Ash Stevens (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.16.5 Ash Stevens (US) Recent Developments
  • 11.17 AMRI (US)
    • 11.17.1 AMRI (US) Corporation Information
    • 11.17.2 AMRI (US) Overview
    • 11.17.3 AMRI (US) High Potency APIs (HPAPI) Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.17.4 AMRI (US) High Potency APIs (HPAPI) Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.17.5 AMRI (US) Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 High Potency APIs (HPAPI) Industry Chain Analysis
  • 12.2 High Potency APIs (HPAPI) Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 High Potency APIs (HPAPI) Production Mode & Process
  • 12.4 High Potency APIs (HPAPI) Sales and Marketing
    • 12.4.1 High Potency APIs (HPAPI) Sales Channels
    • 12.4.2 High Potency APIs (HPAPI) Distributors
  • 12.5 High Potency APIs (HPAPI) Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 High Potency APIs (HPAPI) Industry Trends
  • 13.2 High Potency APIs (HPAPI) Market Drivers
  • 13.3 High Potency APIs (HPAPI) Market Challenges
  • 13.4 High Potency APIs (HPAPI) Market Restraints

14 Key Findings in The Global High Potency APIs (HPAPI) Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer